AstraZeneca
NEWS
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
The latest approval for Brilinta is based on the Phase III THALES trial that showed aspirin plus 90 mg of Brilinta significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischemic stroke or TIA.
It’s a busy time of year for the biopharma industry, as most companies have begun reporting third-quarter financials.
The Oxford and AstraZeneca co-developed COVID-19 vaccine could be one of the first vaccines submitted for regulatory approval, alongside Pfizer and BioNTech’s vaccine candidate BNT162b2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
AstraZeneca is divesting two cardiovascular drugs to Germany’s Cheplapharm Arzneimittel GmbH for $400 million, which will allow the UK pharma giant to reinvest in its main therapy areas.
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
JOBS
IN THE PRESS